The Form 4 filing, an SEC report of an insider's stock trades, was filed on November 16, 2026. It covers purchases from November 13 through November 16, 2026.
Troy Edward Wilson is president and CEO of Kura Oncology (KURA). The company is listed in the healthcare sector and biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | buy |
| Transaction Count | 2 |
| Shares Transacted | 200,000 |
| Price | $7.52 |
| Total Transaction Value | $1,504,765.01 |
| Insider | |
| Ticker Symbol | KURA |
| Company | Kura Oncology, Inc. |
| Insider Name | WILSON TROY EDWARD |
| Insider Title | President and CEO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 635,456 |
| Position Size Change | 31.47% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were two share purchases listed under transaction code P, which identifies a purchase. Both transactions were reported in one filing for one insider.
What was the average price of the transaction?
The average price was $7.52382505 per share, or $7.52 rounded to cents. This average covers both purchases. Separate prices for each purchase were not provided.
How did this transaction affect the insider's holdings?
Troy Edward Wilson bought 200,000 shares and reported owning 635,456 shares afterward. The shares bought made up 31.47% of the shares he owned after these purchases.
What's the total transaction value?
The total value was $1,504,765.01 for the two purchases combined.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement for these purchases. Filing footnotes and any plan details were not provided, so further circumstances remain unknown. The information does not establish why the shares were bought.
For research purposes only; not investment advice.